Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9643788 | 1.00 | LMNA (0.60) | LMNAALDH1A1SIGMAR1TSHRMEN1 | |
| SCHEMBL6707334 | 0.89 | SMN1; SMN2 (0.56) | LMNAALDH1A1TSHRKMT2A | |
| SCHEMBL14859966 | 0.89 | NPC1 (0.67) | LMNAALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL10330737 | 0.89 | SMN1; SMN2 (0.56) | LMNAALDH1A1TSHRKMT2A | |
| SCHEMBL12222591 | 0.88 | ALDH1A1 (0.58) | LMNAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL7549710 | 0.87 | DRD4 (0.56) | LMNAALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL14860601 | 0.86 | KDM4E (0.58) | LMNAALDH1A1SIGMAR1TSHRMEN1 | |
| SCHEMBL14859627 | 0.86 | CCR8 (0.69) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL9217160 | 0.86 | LMNA (0.48) | LMNAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL18466544 | 0.86 | LMNA (0.50) | LMNAALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1072661-C | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 2001-10-10 | — | — | CN | claimed |
| CN-1215395-A | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 1999-04-28 | — | — | CN | claimed |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| EP-1893210-B1 | SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3 | UNIV ILLINOIS (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-20 | — | — | US | disclosed |
| EP-2880020-B1 | ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | UNIV ILLINOIS (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-9663482-B2 | Substituted piperazinyl acetohydrazide procaspase-activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-30 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6352993-B1 | ANTIULCER AGENTS | YUHAN CORPORATION (KR) | 2002-03-05 | — | — | US | disclosed |
| CN-1072661-C | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 2001-10-10 | — | — | CN | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| EP-1015444-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2000-07-05 | — | — | EP | disclosed |
| CN-1215395-A | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 1999-04-28 | — | — | CN | disclosed |
| WO-1998043968-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1998-10-08 | — | — | WO | disclosed |
| US-5519023-A | SCHIZOPHRENIA | ADIR ET COMPAGNIE (FR) | 1996-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | LMNA 337/4885ALDH1A1 926/4885SIGMAR1 3958/4885 |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | LMNA 294/4885ALDH1A1 3075/4885SIGMAR1 4613/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | LMNA 282/4885ALDH1A1 1106/4885SIGMAR1 4213/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | LMNA 282/4885ALDH1A1 1106/4885SIGMAR1 4213/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | LMNA 294/4885ALDH1A1 3075/4885SIGMAR1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.